Sun Pharma's Xelpros, approved by the FDA, is the first and only form of latanoprost that is not formulated with benzalkonium chloride (BAK), a preservative commonly used in topical ocular preparations.
The pharmacist-led series will supply pharmacists, pharmacy technicians and pharmacy owners with the tools to develop patient and prescriber relationships that strengthen their pharmacy’s impact.
The FDA has published 54 product-specific guidances, including 42 new guidances and 12 revised guidances that when finalized will show its expectations on how to develop generic drug products.
The Food and Drug Administration gave clearance for AstraZeneca's Lumoxiti, a new kind of treatment for hairy cell leukemia, which is a rare blood cancer.
Alcon announced plans to locate its future global headquarters in the Canton of Geneva, Switzerland, where it could employ up to 700 people post-Novartis spin-off.
NACDS, WSPA, and NCPA praised CMS for rejecting below-cost Medicaid dispensing fees in Washington State, noting that dispensing fees must cover pharamcies’ costs.
